MONEY MASTER

 Key Takeaway Microsoft is accelerating its artificial intelligence ambitions beyond OpenAI by targeting the healthcare sector — a move aimed at differentiating its Copilot assistant and asserting greater technological independence. Strategic Partnership With Harvard Microsoft is collaborating with  Harvard Medical School’s Health Publishing division  to integrate medically verified content into  Copilot’s next major update , expected as soon as this month. The update will enable Copilot to deliver  credible, practitioner-grade health responses  to users. Microsoft will pay  Harvard a licensing fee  for access to its medical database. The new feature aims to help users manage chronic conditions like  diabetes , providing trustworthy information tailored to individual literacy and language needs. Dominic King , VP of Health at Microsoft AI, said the goal is to ensure users receive  accurate, responsible healthcare information . Copilot’s ...

 Key Highlights Listing timeline:  Early 2026 on Bursa Malaysia Structure:  IPO of up to 1.97B shares (new + existing) Dividend-in-specie:  1 Sunway Healthcare Holdings (SHH) share for every 10 Sunway shares Ownership post-listing:  Sunway to retain  69.5% stake  in SHH Scale:  5 hospitals, 1,662 beds; targeted capacity of 3,400 beds by 2032 Corporate Restructuring & Shareholder Benefit Sunway Bhd (KL:SUNWAY) has unveiled long-awaited plans to list its healthcare subsidiary,  Sunway Healthcare Holdings Bhd (SHH) , by early 2026. Ahead of the IPO, SHH will execute a  1-for-9 share split , increasing its share base from 1.2B to 10.9B, without altering its RM2.2B valuation. SunCity, Sunway’s wholly-owned unit, will distribute SHH shares to Sunway as a  special dividend , which will then be passed on to Sunway shareholders. Each shareholder will receive  1 SHH share for every 10 Sunway shares held , effectively giving investors...

Thomson Medical Group Ltd (SGX: A50)  has launched the  RM18 billion (US$4.3 billion) Johor Bay project , one of Southeast Asia’s largest private healthcare-linked property ventures, signaling its ambition to tap into Malaysia’s growing medical tourism and ageing population trends. Project Highlights Location:  26-acre site within the  Johor-Singapore Special Economic Zone (JS-SEZ) . Healthcare focus: Thomson Hospital Iskandariah  (flagship private hospital). Specialist suites and aged care facilities. Life sciences tower to support medical R&D and biotech. Lifestyle integration: Luxury residences and a  five-star hotel . Commercial and lifestyle precincts for integrated living. Strategic Rationale Rising healthcare demand:  Driven by regional demographic shifts, particularly an ageing population and growing middle-class affluence. Medical tourism catalyst:  Malaysia and Singapore have become key hubs for cross-border medical travel, with Joho...

The healthcare sector heads into one of its busiest earnings weeks in a deep slump. The  S&P 500 Health Care Sector Index  is down 9% in the past year, while managed-care stocks have plunged 50%. Drugmakers and biotech have also struggled, trailing the broader S&P 500’s 17% gain. Who Reports This Week? Tuesday:  UnitedHealth (UNH), Merck (MRK) Wednesday:  Humana (HUM), AbbVie (ABBV) Thursday:  Bristol-Myers Squibb (BMY), CVS Health (CVS) Friday:  Moderna (MRNA) Next Week:  Eli Lilly, Novo Nordisk, Pfizer 4 Big Questions Investors Are Asking: 1️⃣  Can UnitedHealth Recover Under New Leadership? CEO Andrew Witty stepped down; Stephen Helmsley returns to lead. The company pulled its full-year guidance after a 27% stock plunge in April tied to Medicare Advantage woes. Analysts expect new guidance between  $18–$19 EPS , far below last year’s $27.66. 2️⃣  Will Pharma Weather Tariff Risks? Trump signaled  pharma-specific tariffs ...

Ageing population, rising disease rates & digital disruption are rewriting the rules Why It Matters: Malaysia is revamping its healthcare system to prepare for the  future of ageing ,  chronic illness , and  rising costs . According to MBSB Investment Bank’s report at  International Healthcare Week 2025 , sweeping reforms are in motion — and  KPJ Healthcare  is at the center of it all. Key Reform Themes: A geing Nation Alert By 2044, 1 in 10 Malaysians will be over 65! The government plans: Expanded  geriatric care Long-term care insurance Digital literacy & infrastructure for healthy ageing Rise of NCDs (Non-Communicable Diseases) 90% of health burden linked to diabetes, obesity & hypertension. Solutions: PeKaB40 screenings, better primary care &  digital health tools Money Matters Out-of-pocket expenses = 37% of total costs  Reforms include: National Health Fund Mandatory health insurance Lowering individual financial burden...

Top Gainers and Losers (Gap Ups & Downs) – July 17, 2025 Biggest Gap Ups: Lucid Group (LCID)  led the charge with a massive  +20.9%  jump. Auto stocks like  Li Auto (+4.6%)  and industrial players like  Snap-on (+4.1%)  also saw strong bullish gaps. Consumer staples like  PepsiCo (+4.5%)  made notable moves, showing strength beyond tech. Biggest Gap Downs: Abbott Labs (ABT)  declined  -2.6% , leading the day’s pullbacks. Other names like  Starwood Property (-2.1%)  and  Novartis (-1.3%)  also experienced notable gaps down. Lucid’s rally stole the spotlight, while healthcare names took a breather. Top Consecutive Gaps – July 17, 2025 Longest Bullish Streaks: Shinhan Financial Group (SHG)  posted an impressive  14-day  gap-up streak. Deutsche Bank (13 days)  and  British American Tobacco (11 days)  followed closely. Global banks and telecoms appear to be riding strong momentum. Lon...

  Sector Call: UNDERWEIGHT RHB Research maintains a cautious  UNDERWEIGHT  stance on the rubber products sector, citing  prolonged oversupply ,  rising cost pressures , and  shrinking pricing power . Stock Ratings and Target Prices Company Rating Target Price HARTA (5168.MY) SELL RM1.33 KOSSAN (7153.MY) SELL RM1.23 SUPERMX (7106.MY) SELL RM0.54 TOPGLOV (7113.MY) SELL RM0.65 Riverstone (AP4.SG) BUY SGD0.95 Key Sector Challenges 1.  Export Declines Reflect Weak Demand April: -22% MoM glove export drop May: -6% MoM Driven by  slow restocking , lingering inventories, and fading momentum from late 2024 front-loading. 2.  Rising Regional Competition New glove plants in  Indonesia and Vietnam  set to threaten Malaysian exports by  November 2025 . Aggressive pricing by  Chinese manufacturers  further pressurises Malaysian players. 3.  Margin Pressure from Cost Increases Ringgit appreciation  YTD erodes export profit...

Tempus AI Inc. (NASDAQ: TEM)  continues to draw strong interest from institutional investors, with  Cathie Wood’s ARK Invest  adding to its position in the precision health tech company. In its latest move,  ARK Investment Management purchased 150,563 shares , valued at approximately  US$8.8 million . The majority were acquired through the flagship  ARK Innovation ETF (ARKK) , with a smaller tranche via the  ARK Genomic Revolution ETF (ARKG)  — signaling continued conviction in Tempus’ AI-driven healthcare model. A separate  US$1 million worth of shares  was also added, highlighting ARK's sustained bullish stance. Strategic Expansion in Cancer Detection Tempus has recently  expanded its collaboration with Personalis Inc.  to include  colorectal cancer , alongside existing work in  breast ,  lung , and  immunotherapy monitoring . This bolsters the commercialization of the  NeXT Personal™ MRD (Minimal Res...

JD Health, China’s leading online healthcare platform and pharmacy operator, continues to deliver robust fundamentals with  three-year net profit CAGR projected at 15%  and stable net margins of  6%–7% . Backed by rising demand for digital healthcare, an aging population, and a growing focus on wellness and prevention, JD Health is positioning itself as a  long-term structural growth story  in the consumer healthcare space. Technical Strength The stock has rebounded above its 20-day EMA on stronger volume. The MACD line is trading above its signal, confirming short-term momentum. With support at HKD 41.80, a move toward HKD 44.60 is likely. 📊  Financial Highlights FY Revenue (HKD m) Net Profit (HKD m) 2025F 72,874 4,938 2026F 82,269 5,506 2027F 92,522 6,211 Why We Like JD Health Leader in online pharmacy and integrated healthcare services. Strong scalability with an expanding user base and product portfolio. Resilient e-commerce distribution model in a fas...

PMCK Berhad is strategically positioned to capture  underserved demand for private healthcare services in northern Malaysia , driven by macroeconomic tailwinds, an ageing population, and rising insurance penetration. With a fair value of  RM0.26 , the stock offers compelling upside potential based on small-cap healthcare sector valuation metrics. 1️⃣  Expansion into High-Growth Region: PMC Kulim to Double Capacity PMCK is developing a  12-storey, 90-bed private medical centre in Kulim , Kedah, targeting 1QCY2028 commencement. The new facility consolidates operations and expands PMCK’s footprint in a region with  limited private healthcare capacity  (only  7.72 beds per 10,000 population , vs.  17.71 in Kuala Lumpur ). Target market includes  elderly-rich states : Kedah (9.1% elderly), Perlis (8.2%), and Penang (8.0%) — all  above national average . Offers significant room to grow from current  121 operational beds , already represen...

The US House of Representatives has passed a sweeping  US$3.4 trillion tax and spending package , clearing the way for President Trump to sign it into law by Independence Day. While partisan debate continues over its merits, markets are preparing for the ripple effects across equities, bonds, sectors, and currencies. Here’s what investors need to know. What's in the Bill? A Breakdown of Key Components US$4.5 trillion in tax cuts Corporate tax reductions Higher standard deductions for seniors Exemptions for tips and overtime income Expanded Child Tax Credit Spending Cuts Over  US$1 trillion trimmed from Medicaid Rollback of various safety-net programs Sunset clauses for certain clean energy subsidies Increased Defense and Immigration Spending Boosts to Pentagon budget Enhanced funding for border security and enforcement No Revenue from Tariffs Accounted for Yet Treasury suggests up to  US$2 trillion  in potential tariff income not yet included in CBO scoring Investmen...